526 related articles for article (PubMed ID: 36759557)
1. Targeting galectin-driven regulatory circuits in cancer and fibrosis.
Mariño KV; Cagnoni AJ; Croci DO; Rabinovich GA
Nat Rev Drug Discov; 2023 Apr; 22(4):295-316. PubMed ID: 36759557
[TBL] [Abstract][Full Text] [Related]
2. The universe of galectin-binding partners and their functions in health and disease.
Troncoso MF; Elola MT; Blidner AG; Sarrias L; Espelt MV; Rabinovich GA
J Biol Chem; 2023 Dec; 299(12):105400. PubMed ID: 37898403
[TBL] [Abstract][Full Text] [Related]
3. Engineering galectin-glycan interactions for immunotherapy and immunomodulation.
Farhadi SA; Hudalla GA
Exp Biol Med (Maywood); 2016 May; 241(10):1074-83. PubMed ID: 27229902
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of targeting galectins - A biomaterials-focused perspective.
Martin-Saldaña S; Chevalier MT; Pandit A
Biomaterials; 2022 Jul; 286():121585. PubMed ID: 35623267
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings.
Laderach DJ; Compagno D; Toscano MA; Croci DO; Dergan-Dylon S; Salatino M; Rabinovich GA
IUBMB Life; 2010 Jan; 62(1):1-13. PubMed ID: 20014236
[TBL] [Abstract][Full Text] [Related]
6. Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.
Videla-Richardson GA; Morris-Hanon O; Torres NI; Esquivel MI; Vera MB; Ripari LB; Croci DO; Sevlever GE; Rabinovich GA
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008740
[TBL] [Abstract][Full Text] [Related]
7. Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases.
Ahmed R; Anam K; Ahmed H
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175823
[TBL] [Abstract][Full Text] [Related]
8. Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.
Wdowiak K; Francuz T; Gallego-Colon E; Ruiz-Agamez N; Kubeczko M; Grochoła I; Wojnar J
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29320431
[TBL] [Abstract][Full Text] [Related]
9. Galectin binding to cells and glycoproteins with genetically modified glycosylation reveals galectin-glycan specificities in a natural context.
Nielsen MI; Stegmayr J; Grant OC; Yang Z; Nilsson UJ; Boos I; Carlsson MC; Woods RJ; Unverzagt C; Leffler H; Wandall HH
J Biol Chem; 2018 Dec; 293(52):20249-20262. PubMed ID: 30385505
[TBL] [Abstract][Full Text] [Related]
10. Role of Galectins in Tumors and in Clinical Immunotherapy.
Chou FC; Chen HY; Kuo CC; Sytwu HK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
[TBL] [Abstract][Full Text] [Related]
11. Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy.
Ko FCF; Yan S; Lee KW; Lam SK; Ho JCM
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371482
[TBL] [Abstract][Full Text] [Related]
12. Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy.
Lau LS; Mohammed NBB; Dimitroff CJ
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555198
[TBL] [Abstract][Full Text] [Related]
13. Methods of in vitro study of galectin-glycomaterial interaction.
Heine V; Dey C; Bojarová P; Křen V; Elling L
Biotechnol Adv; 2022 Sep; 58():107928. PubMed ID: 35189272
[TBL] [Abstract][Full Text] [Related]
14. Re-wiring regulatory cell networks in immunity by galectin-glycan interactions.
Blidner AG; Méndez-Huergo SP; Cagnoni AJ; Rabinovich GA
FEBS Lett; 2015 Nov; 589(22):3407-18. PubMed ID: 26352298
[TBL] [Abstract][Full Text] [Related]
15. Chemokines modulate glycan binding and the immunoregulatory activity of galectins.
Sanjurjo L; Schulkens IA; Touarin P; Heusschen R; Aanhane E; Castricum KCM; De Gruijl TD; Nilsson UJ; Leffler H; Griffioen AW; Elantak L; Koenen RR; Thijssen VLJL
Commun Biol; 2021 Dec; 4(1):1415. PubMed ID: 34931005
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of galectin-3 inhibition in fibrotic disease.
Slack RJ; Mills R; Mackinnon AC
Int J Biochem Cell Biol; 2021 Jan; 130():105881. PubMed ID: 33181315
[TBL] [Abstract][Full Text] [Related]
17. Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells.
Patnaik SK; Potvin B; Carlsson S; Sturm D; Leffler H; Stanley P
Glycobiology; 2006 Apr; 16(4):305-17. PubMed ID: 16319083
[TBL] [Abstract][Full Text] [Related]
18. An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present).
Sethi A; Sanam S; Alvala R; Alvala M
Expert Opin Ther Pat; 2021 Aug; 31(8):709-721. PubMed ID: 33749494
[TBL] [Abstract][Full Text] [Related]
19. Untangling Galectin-Driven Regulatory Circuits in Autoimmune Inflammation.
Toscano MA; Martínez Allo VC; Cutine AM; Rabinovich GA; Mariño KV
Trends Mol Med; 2018 Apr; 24(4):348-363. PubMed ID: 29555188
[TBL] [Abstract][Full Text] [Related]
20. Tissue-specific control of galectin-1-driven circuits during inflammatory responses.
Cutine AM; Bach CA; Veigas F; Merlo JP; Laporte L; Manselle Cocco MN; Massaro M; Sarbia N; Perrotta RM; Mahmoud YD; Rabinovich GA
Glycobiology; 2021 Sep; 31(8):891-907. PubMed ID: 33498084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
